{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:46:34Z","timestamp":1786995994372,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prnil.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:46:26Z","timestamp":1741639586000},"page":"161-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of tamsulosin 0.4 mg for the treatment in male with the international Prostate Symptom Score \u2265 20 compared with tamsulosin 0.2 mg"],"prefix":"10.1016","volume":"13","author":[{"given":"Yu Seob","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-3623","authenticated-orcid":false,"given":"Sung Chul","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prnil.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1442-2042.2008.02003.x","article-title":"Prevalence of chronic prostatitis symptoms in a randomly surveyed adult population of urban-community-dwelling Nigerian males","volume":"15","author":"Ejike","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.prnil.2025.03.002_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/aja.2012.127","article-title":"Relationship between age and prostate size","volume":"15","author":"Zhang","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.prnil.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.05.021","article-title":"Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations","volume":"121","author":"Hoke","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.prnil.2025.03.002_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4111\/icu.20230249","article-title":"The epidemiology of male lower urinary tract symptoms associated with benign prostatic hyperplasia: results of 20 years of Korean community care and surveys","volume":"65","author":"Jeh","year":"2024","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.prnil.2025.03.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prnil.2023.01.002","article-title":"Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures","volume":"11","author":"Franco","year":"2023","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0094-0143(21)00977-0","article-title":"Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia","volume":"17","author":"Caine","year":"1990","journal-title":"Urol Clin"},{"key":"10.1016\/j.prnil.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003495-199346010-00010","article-title":"Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia","volume":"46","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.prnil.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-200262010-00006","article-title":"Tamsulosin: an update of its role in the management of lower urinary tract symptoms","volume":"62","author":"Lyseng-Williamson","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.prnil.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00002512-200219020-00004","article-title":"Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms","volume":"19","author":"Dunn","year":"2002","journal-title":"Drugs Aging"},{"key":"10.1016\/j.prnil.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0022-5347(17)39620-9","article-title":"Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group","volume":"144","author":"Kawabe","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3349\/ymj.2016.57.2.407","article-title":"Is tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers?: a meta-analysis and a moderator focused study","volume":"57","author":"Shim","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.prnil.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1185\/03007995.2014.980887","article-title":"General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"31","author":"Shim","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.prnil.2025.03.002_bib13","first-page":"E466","article-title":"Efficacy of dose escalation of tamsulosin for the treatment in symptomatic benign prostatic hyperplasia of lower urinary tract symptoms: a randomised, double-blind, phase 3 trial in Korean men","volume":"195","author":"Kim","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.03.002_bib14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/03007995.2018.1447451","article-title":"Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial","volume":"34","author":"Chung","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.prnil.2025.03.002_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4111\/kju.2011.52.7.479","article-title":"Efficacy and tolerability of tamsulosin 0.4 mg in patients with symptomatic benign prostatic hyperplasia","volume":"52","author":"Chung","year":"2011","journal-title":"Korean J Urol"},{"key":"10.1016\/j.prnil.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1757-5672.2012.00141.x","article-title":"Efficacy of dose escalation of tamsulosin for the treatment of lower urinary tract symptoms","volume":"4","author":"Kim","year":"2012","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.prnil.2025.03.002_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5213\/inj.1734826.413","article-title":"Evidence is enough?: a systematic review and network meta-analysis of the efficacy of tamsulosin 0.2 mg and tamsulosin 0.4 mg as an initial therapeutic dose in asian benign prostatic hyperplasia patients","volume":"21","author":"Kim","year":"2017","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.prnil.2025.03.002_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5213\/inj.1734962.481","article-title":"Letter to the editor: Commentary on \"evidence is Enough?: a systematic review and network meta-analysis of the efficacy of tamsulosin 0.2 mg and tamsulosin 0.4 mg as an initial therapeutic dose in Asian benign prostatic hyperplasia patients\"","volume":"21","author":"Tae","year":"2017","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.prnil.2025.03.002_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5213\/inj.1734986.493","article-title":"The authors reply: reply on \"evidence is Enough?: a systematic review and network meta-analysis of the efficacy of tamsulosin 0.2 mg and tamsulosin 0.4 mg as an initial therapeutic dose in Asian benign prostatic hyperplasia patients\"","volume":"21","author":"Kim","year":"2017","journal-title":"Int Neurourol J"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:57:26Z","timestamp":1758128246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S228788822500008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S228788822500008X"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.03.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of tamsulosin 0.4 mg for the treatment in male with the international Prostate Symptom Score \u2265 20 compared with tamsulosin 0.2 mg","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}